The present disclosure, in particular, for use in the treatment of cancer relates to pharmaceutical combination comprising a (a) Mdm2 inhibitor and (b) (i) MEK inhibitors and / or (b) (ii) Bcl2 inhibitors . The present disclosure also relates to the use of such combination for the preparation of a medicament for the treatment of cancer, a method of treating cancer in a subject in need thereof, the combination of co-therapeutically effective amount comprising administering an object to the subject, to commercial packaging such combination pharmaceutical comprising the compositions and to it.